Tag Archives: Agilent Technologies

September, 2018

27 September
Agilent to Expand Portfolio and Capabilities in Cell Analysis with Acquisition of ACEA Biosciences

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire privately-owned ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis instruments for life science research and clinical diagnostics, for $250 million in cash. “Expanding our cell analysis footprint is a key strategic …
Share

22 August
FDA Expands Approval of Agilent’s Companion Diagnostic in Urothelial Carcinoma

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma. The assay is now approved to identify patients with urothelial carcinoma who may benefit from KEYTRUDA, an anti-PD-1 …
Share

13 June
Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use. Physicians in the United States can now gain valuable information to help them identify cervical cancer patients who are most likely …
Share

5 April
Agilent Technologies to Acquire Lasergen for $105 Million

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) and Lasergen, Inc. (Lasergen) today announced that they have signed a definitive agreement for Agilent to acquire the remaining shares of Lasergen, an emerging biotechnology company focused on research and development of innovative technologies for DNA sequencing, for $105 million. In March 2016 …
Share

24 March
Hematogenix’s PD-L1 Companion Diagnostic Tests Now Available

Tinley Park, IL, March 24, 2016 –(PR.com)– Hematogenix Laboratory Services (Hematogenix), a leader in the field of integrated pathology services for drug development and clinical testing, announces the availability of the U.S. Food and Drug Administration (FDA) approved companion diagnostic assays, PD-L1 IHC 22C3 pharmDx and PD-L1 IHC 28-8 pharmDx. …
Share